FDA Grants Fast Track Designation to Sellas Life Sciences’ SLS009 for Lymphoma
SLS009 is a novel CDK9 inhibitor under investigation for the treatment of relapsed/refractory peripheral T-cell lymphomas.
Sellas Life Sciences announced that the FDA has granted Fast Track Designation to SLS009, its novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL). The designation intends to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.1
“The FDA’s decision to grant SLS009 Fast Track designation signifies an important milestone towards developing a safe and effective treatment for PTCL, a group of aggressive and rare non-Hodgkin lymphomas, and underscores the urgent need for innovative therapies such as SLS009 that can significantly improve the outcome of PTCL patients,” said Angelos Stergiou, MD, ScD hc, president, CEO, Sellas, in a company press release. “SLS009 has demonstrated very promising clinical responses in PTCL patients in the recently completed dose-escalation portion of the Phase 1 trial in relapsed/refractory hematological malignancies and with the Fast Track designation we are poised to accelerate its development. We are committed to working closely with the FDA and our partner GenFleet Therapeutics to develop this promising treatment for patients in need.”
R/R PTLC is an aggressive form of lymphoma with an overall survival rate of six months. Currently, most approved therapies have overall response rates of less than 30%, low complete response rates, and short progression-free survival.2
According to Sellas, SLS009 demonstrated favorable safety and tolerability, as well as promising clinical efficacy in the recently completed dose-escalation portion of the phase 1 trial in r/r hematological malignancies, with responses observed in acute myeloid leukemia and lymphoma patients, among whom four out of eleven patients with PTCL (36.4%) achieved clinical responses, including one in continuous treatment for more than 56 weeks.1
The PTCL study, which is expected to enroll up to 95 patients, is fully funded by GenFleet Therapeutics (Shanghai) Inc. Sellas stated that it is also aiming to earn Breakthrough Therapy designation by the FDA with a meeting scheduled to discuss the possibility later this year.
References
1. SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas. GlobeNewswire. October 30, 2023. Accessed November 1, 2023. https://www.globenewswire.com/news-release/2023/10/30/2769302/0/en/SELLAS-Life-Sciences-Receives-Fast-Track-Designation-from-FDA-for-SLS009-for-Treatment-of-Relapsed-Refractory-Peripheral-T-cell-Lymphomas.html
2. American Society of Hematology. 44 Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results. https://ash.confex.com/ash/2020/webprogram/Paper140412.html#:~:text=Relapsed%20or%20refractory%20(R%2FR,progression%20free%20survival%20(PFS). Accessed November 1, 2023.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
